APEX BIOVENTURES ACQUISITION CORP

Apex Bioventures Acquisition Corp, which traded under the ticker PEX, filed its S-1 registration statement with the SEC on July 13, 2006, entering the market as a blank-check company focused on the life sciences and biotechnology sector. The vehicle was part of an early wave of sector-focused SPACs that emerged in the mid-2000s, seeking acquisition candidates within the bioventure space at a time when the SPAC structure was gaining renewed institutional attention. With a filing history now spanning two decades, the company has long since concluded its SPAC lifecycle. For complete historical filing data, deal timelines, and sponsor profiles on PEX and thousands of other SPACs, sign up for full access at SpacDesk.